20-F: argenx SE Reports Strong 2025 with $4.2B Sales, Pipeline Advances

argenx SE achieved significant operational and financial milestones in 2025, including record product net sales of $4.2 billion and substantial progress across its immunology pipeline.

Summary

• Product net sales increased by 90% to $4.2 billion in 2025, up from $2.2 billion in 2024, driven by global commercialization of VYVGART.
• The company reported a profit of $1.3 billion for 2025, marking its second consecutive year of profitability, compared to $0.8 billion in 2024.
• VYVGART reached over 19,000 patients across three indications (gMG, CIDP, ITP) and three product presentations, including the successful launch of the prefilled syringe (PFS).
• Positive topline data was reported from the ADAPT-SERON Phase 3 clinical trial in Seronegative gMG, with a supplemental BLA accepted for priority review and an expected PDUFA date of May 10, 2026.
• Positive data from the ADAPT-OCULUS clinical trial in Ocular MG was also reported in February 2026, meeting its primary endpoint.
• The pipeline advanced with 10 ongoing registrational clinical trials and the addition of four new Phase 1 molecules (ARGX-213, ARGX-124, ARGX-118, ARGX-125, TSP-101).
• Research and development expenses increased by $0.4 billion to $1.4 billion in 2025, reflecting continued investment in the product candidate portfolio.
• Selling, general and administrative expenses rose by $0.3 billion to $1.4 billion, primarily due to scaling commercial operations and digital technology infrastructure.
• Cash and cash equivalents increased to $3.5 billion as of December 31, 2025, up from $1.5 billion in 2024, providing strong financial flexibility.
• The company's total assets grew to $8.7 billion in 2025 from $6.2 billion in 2024, reflecting operational growth.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this filing as highly positive, reflecting exceptional financial growth, significant pipeline advancements, and strong commercial execution for its lead product, VYVGART. The company's strategic vision and successful leadership transition further bolster confidence.

Positives

• Product net sales surged by 90% to $4.2 billion in 2025, demonstrating strong commercial execution.
• Achieved a profit of $1.3 billion in 2025, marking the second year of profitability and first year of operational profitability.
• VYVGART reached over 19,000 patients globally across gMG, CIDP, and ITP, expanding its market impact.
• Successful launch of the VYVGART Hytrulo prefilled syringe (PFS) in the U.S., EU, and Japan, offering more convenient treatment options.
• Positive topline results from the ADAPT-SERON Phase 3 clinical trial in Seronegative gMG, supporting label expansion.
• Positive data from the ADAPT-OCULUS clinical trial in Ocular MG, meeting its primary endpoint.
• Advanced 10 ongoing registrational clinical trials and brought forward four new Phase 1 molecules, strengthening the pipeline.
• Cash and cash equivalents increased significantly to $3.5 billion, providing robust financial strength for future investments.
• The 2025 Remuneration Policy received strong shareholder endorsement with approximately 96% approval, reflecting alignment on executive compensation.
• The company's leadership transition plan for CEO and Board Chairperson was announced with overwhelmingly positive shareholder feedback.

Negatives

• Accumulated losses of $0.3 billion as of December 31, 2025, despite two years of profitability, indicate historical losses.
• Research and development expenses increased by $0.4 billion to $1.4 billion, and selling, general and administrative expenses increased by $0.3 billion to $1.4 billion, reflecting rising operational costs.
• The company faces intense competition in the biopharmaceutical market, including from biosimilar products, which could erode future sales and pricing power.
• Potential for regulatory changes, such as the EU Pharmaceutical Legislation reform, could shorten market exclusivity periods for medicinal products.
• Uncertainty regarding the full economic impact of the U.S. Inflation Reduction Act (IRA) and potential MFN pricing initiatives could reduce product prices and increase rebate obligations.

Risks

• Commercial success of products and product candidates depends on market acceptance by physicians, patients, medical community, and healthcare payors.
• Significant competition exists in drug discovery and development from large pharmaceutical companies and those utilizing AI, potentially impacting market share and talent acquisition.
• Challenges in successfully commercializing products in new indications or markets, requiring expansion of sales and marketing, which is expensive and time-consuming.
• Biological products, including VYVGART, may face biosimilar competition, potentially leading to decreased sales or lower prices.
• Enacted and future legislation and regulations, such as the IRA and EU Pharmaceutical Legislation, could impact demand, pricing, and reimbursement for products.
• Failure to obtain or maintain adequate pricing, coverage, or reimbursement status for products and product candidates from third-party payors.
• Inability to obtain or maintain orphan drug designation or exclusivity could lead to competitors selling products for the same conditions.
• Failure to successfully identify, select, and develop products in other indications or additional product candidates could impair growth.
• Clinical trials may not succeed, or regulatory approval may be delayed or denied due to various factors, including design disagreements, insufficient data, or manufacturing issues.
• Products and product candidates may have serious adverse side effects, leading to clinical trial interruptions, restrictive labeling, or withdrawal of approvals.
• Target patient populations may be smaller than expected, or difficulties in patient enrollment and retention in clinical trials could delay development.
• Reliance on third parties for research, manufacturing, and clinical trials poses risks if relationships are unsuccessful or performance is substandard.
• Disruptions in the worldwide supply chain for raw materials and manufacturing processes could delay product development and commercialization.
• Accuracy and timing of financial reporting are partially dependent on information from third-party partners, which is not controlled by the company.
• Exposure to costly and damaging product liability and professional indemnity claims inherent in pharmaceutical product development and marketing.
• Strategic transactions, including acquisitions, collaborations, or investments, may not realize anticipated benefits and could be expensive or time-consuming.
• Business and operations could suffer from system failures or unauthorized access to IT systems, including cyber-attacks and data breaches.
• Inability to adequately maintain, enforce, or protect intellectual property rights could adversely affect competitive advantage.
• Intellectual property litigation could divert substantial resources or result in patents being found invalid or unenforceable.
• Future growth and ability to compete depend on maintaining company culture, retaining key personnel, and recruiting additional qualified personnel.
• Global geoand socio-political threats and macro-economic uncertainty could materially and adversely affect business and financial performance.
• Exposure to unanticipated changes in tax laws and regulations, adjustments to tax provisions, or additional tax liabilities.
• Difficulties efficiently managing growth and expanding development, regulatory, and sales and marketing capabilities could disrupt operations.
• Holders of ADSs have fewer rights than ordinary shareholders, and the price of ADSs may be volatile.
• Claims of U.S. civil liabilities may not be enforceable against the company or its management/directors due to non-U.S. domicile and asset location.
• Loss of foreign private issuer status would require compliance with the Exchange Act's domestic reporting regime, incurring significant expenses.
• Classification as a passive foreign investment company (PFIC) for U.S. federal income tax purposes could result in adverse U.S. tax consequences for certain U.S. holders.

Future Outlook

argenx SE's 2026 outlook focuses on three strategic priorities: expanding global patient impact with VYVGART through broader adoption and label expansions, shaping the future of FcRn medicines with innovative delivery and combination approaches, and accelerating empasiprubart and a diversified pipeline of first-in-class molecules. The company aims to achieve its Vision 2030 goals of treating 50,000 patients globally, securing 10 labeled indications, and advancing five pipeline candidates into Phase 3 development. Key registrational readouts are expected in 2026 for Ocular MG, Myositis, and MMN, and in 2027 for SjD and CIDP.

Management Comments

• Our success in generating long-term value creation for our stakeholders depends on our ability to discover and develop innovative medicines that address unmet medical needs, and our ability to successfully bring those medicines to patients and ultimately generate financial returns for our shareholders.
• We strongly believe our long-term success depends on our ability to attract, grow and retain exceptional talent focused on the execution of our business objectives, while promoting and upholding our identity and core values our Cultural Pillars along the way.
• 2025 was a year of strong execution as we advanced our long-term commitment to patients under Vision 2030: aiming to treat 50,000 patients globally, secure 10 labeled indications across all approved medicines, and advance five pipeline candidates into Phase 3 development by 2030.
• Throughout 2025, VYVGART continued to deliver meaningful impact for patients globally, reaching more than 19,000 patients across three indications (gMG, CIDP, and ITP) and three product presentations.
• This strong commercial execution resulted in a milestone for the Company, with VYVGART surpassing $1 billion in product net sales in a single quarter for the first time in the third quarter of 2025.
• We are delighted to receive overwhelmingly positive feedback from shareholders since the announcement of the leadership transition and strong support for both Tim Van Hauwermeiren and Karen Masseys new roles.
• We are confident that with Tim Van Hauwermeiren as the Non-Executive chairperson of the Board of Directors and Karen Massey as CEO, argenx is extremely well-positioned for the long term.

Industry Context

StockSavvy.ai notes that argenx SE's strong performance in 2025, particularly with VYVGART's commercial success and pipeline advancements, positions it as a significant player in the highly competitive autoimmune and neuromuscular disease markets. The company's focus on first-in-class and best-in-class therapies, coupled with its Immunology Innovation Program (IIP), aligns with broader industry trends emphasizing novel biology and differentiated mechanisms of action. The expansion of VYVGART into new indications and formulations, such as the PFS, reflects a strategic response to patient needs and market demand, a common driver for growth in specialized pharmaceutical sectors. However, the industry faces increasing scrutiny on drug pricing and potential biosimilar competition, as highlighted by the U.S. Inflation Reduction Act and EU legislative reforms, which could impact future revenue streams. argenx's proactive approach to intellectual property protection and global commercialization efforts are critical in navigating this dynamic landscape, where competitors like AstraZeneca, AbbVie, and Novartis are also heavily invested.

Comparison to Industry Standards

• argenx SE's 90% increase in product net sales to $4.2 billion in 2025 significantly outperforms many established biopharmaceutical companies, indicating strong market penetration and adoption for VYVGART in its approved indications.
• The achievement of over $1 billion in quarterly product net sales for VYVGART in Q3 2025 demonstrates a rapid commercial ramp-up, comparable to blockbuster drug launches seen from larger pharmaceutical players like AbbVie's Humira or Regeneron's Eylea in their early commercial phases, especially considering VYVGART targets rare diseases.
• The company's R&D expenditure of $1.4 billion in 2025, representing a 39% increase, is substantial and indicative of a high-growth biotech firm aggressively investing in its pipeline, aligning with industry leaders who prioritize innovation to maintain competitive edge.
• The successful development and regulatory progress of efgartigimod in multiple indications (gMG, CIDP, ITP, Seronegative gMG, Ocular MG) positions it as a foundational FcRn-based therapy, a strategy similar to how companies like Alexion Pharmaceuticals (now AstraZeneca) built franchises around complement inhibitors for rare diseases.
• The expansion to 1,863 full-time employees by December 31, 2025, with fully staffed commercial teams in key global markets, reflects a rapid scaling typical of companies transitioning from a development-stage to a commercial-stage enterprise, comparable to the growth trajectories of companies like Moderna or BioNTech during their commercialization phases.

Management Changes

Corporate Governance

Related Party Transactions

• The company has an investment in OncoVerity, Inc., a joint venture with the University of Colorado Anschutz Medical Campus and UCHealth, focused on cusatuzumab development. argenx contributed $7 million in 2025.
• From time to time, in the ordinary course of business, the company may contract for services from companies in which certain members of senior management or directors may serve as director or advisor, with costs negotiated on an arms-length basis and not material.
• The CEO, Tim Van Hauwermeiren, has a management agreement with a base pay of $827,160 and a cash bonus maximum of 60% of base pay. This agreement will be terminated upon his transition to Non-Executive Chairperson.
• Karen Massey (COO), Karl Gubitz (CFO), Peter Ulrichts (CSO), Arjen Lemmen (VP Corporate Development & Strategy), Andria Wilk (Global Head of Quality), and Luc Truyen (CMO) have employment contracts with subsidiaries for indefinite terms.
• Malini Moorthy (General Counsel and Corporate Secretary) has an employment contract with argenx US and a secondment agreement to argenx B.V. in Belgium, extended through December 31, 2026.
• Indemnification agreements are in place with each Non-Executive Director and Senior Management Team member.

Stakeholder Impact

• **Shareholders:** Positive impact due to strong financial performance, increased profitability, and significant pipeline progress, potentially leading to increased share value. The new remuneration policy aims to align management incentives with long-term shareholder value creation.
• **Employees:** Continued growth in headcount (1,863 employees in 2025) and investment in R&D and commercial teams indicate job creation and career opportunities. The equity incentive plan and remuneration policy are designed to attract and retain talent, though some aspects of the remuneration policy deviate from Dutch corporate governance best practices.
• **Patients:** Direct positive impact through the commercialization of VYVGART, reaching over 19,000 patients across multiple indications, and the development of new formulations like the PFS for more convenient treatment. The extensive pipeline and ongoing clinical trials aim to address unmet medical needs in severe autoimmune and neuromuscular diseases.
• **Customers (Healthcare Providers & Payors):** Increased availability of VYVGART and its new formulations, but also potential for pricing pressures and complex reimbursement negotiations due to government regulations and third-party payor policies.
• **Suppliers & Partners:** Continued reliance on third-party manufacturers (e.g., Lonza, Fujifilm) and collaboration partners (e.g., Zai Lab, Halozyme) indicates ongoing business for these entities, but also exposes the company to supply chain risks and dependence on their performance.
• **Regulatory Bodies:** Ongoing compliance with extensive healthcare laws and regulations in multiple jurisdictions (U.S., EU, Japan, China, etc.) is critical, with potential for enforcement actions and penalties for non-compliance. The company's engagement with new regulations like the AI Act and CSRD reflects evolving compliance demands.

Next Steps

• Continue to impact more patients globally with VYVGART, driving broader adoption and unlocking new opportunities with potential label expansions.
• Shape the long-term future of FcRn medicines by advancing future FcRn molecules, innovative delivery modalities, and combination approaches.
• Deliver the next wave of immunology innovation by accelerating empasiprubart and a diversified pipeline of first-in-class molecules.
• Expect topline results in Q1 2026 for Ocular MG (ADAPT OCULUS) with efgartigimod.
• Expect topline results in Q3 2026 from the ALKIVIA clinical trial evaluating three myositis subsets (IMNM, ASyS, and DM) with efgartigimod.
• Expect topline results in Q4 2026 for the EMPASSION clinical trial (MMN) with empasiprubart.
• Expect topline results in Q4 2026 for primary ITP (ADVANCE-NEXT) with efgartigimod.
• Expect topline results from the UNITY clinical trial (SjD) in 2H 2027 with efgartigimod.
• Expect topline results from the EMVIGORATE clinical trial for empasiprubart (CIDP) in 2H 2027.
• Initiate a Phase 3 clinical trial for adimanebart in CMS in Q3 2026.
• Three new molecules (ARGX-118, ARGX-125, TSP-101) are expected to enter Phase 1 clinical trials in 2026.
• Tim Van Hauwermeiren will transition to Non-Executive Chairperson of the Board of Directors, subject to shareholder approval at the 2026 General Meeting.
• Karen Massey is envisaged to be appointed as an Executive Director and subsequently elected as CEO by the Board of Directors at the 2026 General Meeting.

Key Dates

Recommendation

argenx SE's 2025 performance demonstrates exceptional growth, with product net sales nearly doubling and a significant increase in profitability. The successful launch of VYVGART's prefilled syringe and positive clinical trial results for new indications (Seronegative gMG, Ocular MG) de-risk future revenue streams and expand market potential. The robust pipeline, with 10 ongoing registrational trials and new molecules entering Phase 1, indicates strong long-term growth prospects. While R&D and SG&A expenses are rising, they are commensurate with aggressive global expansion and innovation. The strong cash position provides financial flexibility. Despite competitive and regulatory risks inherent in the biopharmaceutical industry, the company's execution and strategic vision make it a compelling 'strong buy' for investors seeking growth in the immunology space.

Keywords

Immunology, Biopharmaceutical, FcRn inhibitor, VYVGART, Efgartigimod, gMG, CIDP, ITP, Empasiprubart, Adimanebart, Clinical Trials, Regulatory Approval, Drug Development, Rare Diseases, Autoimmune Diseases, Neuromuscular Diseases, Biologics, Pharmaceutical Sales, Pipeline, R&D, SEC Filing, 20-F